Endometrial cancer or uterine cancer is one of the most common gynecological cancers and 2.8% of women are diagnosed with the endometrial cancer at some point in their lives. According to National Cancer Institute statistics, in 2015 endometrial cancer contributed to 1.8% of all cancers and 3.6% of all new cancer cases were diagnosed as endometrial cancer. Early detection of endometrial cancer helps in the selection of proper treatment options. Endometrial cancers are typically diagnosed as type I and type II tumors and majority of the patients diagnosed with endometrial cancer represent early-stage cancers. According to Yale University School of Medicine, U.S., in 2014, type I tumors constitute 80% of all cases of endometrial cancers diagnosed in the U.S. Endometrial cancer can be treated by one or combination of chemotherapy, radiation therapy and hormone therapy. Most of the physicians recommend combination treatments as chemotherapy alone has traditionally been deem ineffective. Adjuvant radiation therapy is preferred in patients who have diagnosed with sage I or II endometrial cancer. Radiation therapy is also recommended in patients who have undergone the surgery, in order to avoid the relapse of endometrial cancer. Endometrial cancer is often detected in women above the age of 50 years and risk of endometrial cancer increases with the age. Also the risk of development of endometrial cancer is more in breast cancer patients who are being treated with tamoxifen or estrogen for long time. Plenty of chemotherapeutic agents are available and are recommended in the combination for the treatment of endometrial cancer. Some of the combination therapies include carboplatin & paclitaxel, Cisplatin & doxorubicin, Carboplatin & docetaxel and others.
Endometrial Cancer Treatment Market: Drivers and Restraints
Increasing incidence of uterine serous carcinoma – a highly aggressive variant of endometrial cancer – and relapse of endometrial cancers in patients treated with chemotherapy are the prime factors driving the growth of global endometrial cancer treatment market over the forecast period. In 2014, uterine serous carcinoma represented 10% of all caseload of endometrial cancers in the U.S. Some of the risk factors of endometrial cancer include obesity, presence of polycystic ovarian syndrome, long-term consumption of birth control pills, delayed pregnancy etc. Increasing incidence of obesity in the women aged above 50 can lead to the growth of endometrial cancer treatment market. However, divergent nature of cancer and increasing stringency in the regulatory requirements are the prime factors limiting the growth of global endometrial cancer treatment market. Besides this, side effects related to chemotherapy, radiation therapy and hormone therapy also restricts the adoption of these agents for endometrial cancer treatment.
Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2834
Endometrial Cancer Treatment Market: Segmentation
The global endometrial cancer treatment market has been segmented on the basis of treatment type, end user, and geography.
Based on treatment type, the global endometrial cancer treatment market is divided into following:
- Hormonal Therapy
- Megestrol (Megace)
- Medroxyprogesterone (PROVERA)
- Others (anastrozole, letrozole, etc.)
- Radiation Therapy
- Whole Pelvic External-beam Radiation Therapy
- Vaginal Brachytherapy
- Bilateral Salpingo-oophorectomy (removal of both fallopian tubes and ovaries)
Based on end user, the global endometrial cancer treatment market is segmented as below:
- Retail Pharmacy
- Hospital pharmacy
Endometrial Cancer Treatment Market: Overview
Global market for endometrial cancer treatment is forecast to grow at moderate rate owing to less number of drugs approved for treatment of endometrial cancer. Despite of this, chemotherapy segment is expected to hold the highest share in the global endometrial cancer treatment market due to high adoption rate of chemotherapy over radiation and surgical treatment. Also chemotherapeutic agents such as carboplatin and paclitaxel are recommended as a first line of therapy in majority of the cases, which increases demand for these products. Recent FDA approval of IXEMPRA (ixabepilone) for use in the treatment of endometrial cancer treatment is expected to fuel the growth of global market over the forecast period.
Endometrial Cancer Treatment Market: Regional Wise Outlook
Geographically, the global endometrial cancer treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America will continue to hold largest share in the global endometrial cancer treatment market due to high incidence of uterine serous carcinoma. Europe is expected to hold the second largest share in the global market partly due to increasing product availability in the region. North America is expected to expand at the highest rate over the forecast period.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-2834
Endometrial Cancer Treatment Market: Key Players
Some of the players operating in the global endometrial cancer treatment market include R-Pharm-US LLC., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca Plc., Novartis AG and others. The global endometrial cancer treatment market is expected to grow in future due to increasing investment by multinational companies in cancer research.